Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup

Impact of Adopting Population Pharmacokinetics for Tailoring Prophylaxis in Haemophilia A Patients: A Historically Controlled Observational Study

(2019) Felix Kallenbach et al.   THROMBOSIS AND HAEMOSTASIS

Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization

(2019) Alanna McEneny-King et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Correction to: Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients

(2019) Pierre Chelle et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

BAX 855, a PEGylated rFVIII product with prolonged half-life

(2018) M. J. Bossard et al.   Hamostaseologie

Clinical outcomes in hemophilia A patients undergoing tailoring of prophylaxis based on population-based pharmacokinetic dosing

(2018) Azusa Nagao et al.   THROMBOSIS RESEARCH

Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit

(2017) D. Garmann et al.   HAEMOPHILIA

In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients

(2017) T. Preijers et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH

(2017) A. Iorio et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A

(2017) Y. Zhang et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A

(2016) Alanna McEneny-King et al.   Expert Opinion on Drug Metabolism & Toxicology

Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients

(2016) B. Brand et al.   HAEMOPHILIA

Population pharmacokinetics of plasma-derived factor IX: procedures for dose individualization

(2016) A. Brekkan et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A

(2015) B. A. Konkle et al.   BLOOD

A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children

(2015) Anna-Karin Hamberg et al.   BMC Medical Informatics and Decision Making

Prediction of Fat-Free Mass in Children

(2015) Hesham Saleh Al-Sallami et al.   CLINICAL PHARMACOKINETICS

Safety of PEGylated recombinant human full-length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates

(2015) R. Stidl et al.   HAEMOPHILIA

Individualizing prophylaxis in hemophilia: a review

(2015) Pia Petrini et al.   Expert Review of Hematology

Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS

(2013) S. Lalezari et al.   HAEMOPHILIA

Personalized prophylaxis

(2012) P. W. COLLINS   HAEMOPHILIA

Safe and Effective Variability—A Criterion for Dose Individualization

(2012) Nicholas H.G. Holford et al.   THERAPEUTIC DRUG MONITORING

Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models

(2011) Martin Bergstrand et al.   AAPS Journal

Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A

(2010) S. BJÖRKMAN   HAEMOPHILIA

Handling Data Below the Limit of Quantification in Mixed Effect Models

(2009) Martin Bergstrand et al.   AAPS Journal

A study of variations in the reported haemophilia A prevalence around the world

(2009) J. S. STONEBRAKER et al.   HAEMOPHILIA